Rare cancers should not be second-class citizens of cancer research
In the vast landscape of cancer research, where resources tend to gather around the most common diseases, a small and overlooked tumor of the kidney has become a symbol of a deeper inequity. Antonio Lázaro Sánchez, an oncologist in Murcia, Spain, has published a systematic review revealing that immunotherapy combinations can produce durable remissions in Bellini's collecting duct carcinoma — a disease so rare that most physicians never encounter it, and so neglected that patients have long faced decisions made in near-total darkness. His findings are both a clinical signal and a moral argument: that rarity should not determine the quality of care a person receives.
- Patients with metastatic Bellini's collecting duct carcinoma once faced median survival under a year, with no dedicated trials and no standard of care to guide their doctors.
- A systematic review of 24 studies and over 300 patients reveals that immunotherapy combinations can produce complete remissions lasting up to six years — a striking departure from the disease's historically grim trajectory.
- The deeper tension is structural: cancer research funding flows toward prevalence, leaving rare cancer patients to rely on evidence borrowed from unrelated diseases and small, fragmented case series.
- Lázaro Sánchez is calling for international patient registries, adaptive trial designs, and biomarker-driven studies to extract meaningful knowledge from inherently small populations.
- The field now faces a choice — whether to treat these findings as a prompt for coordinated, equitable action, or allow rare cancers to remain at the margins of oncological progress.
Antonio Lázaro Sánchez, a medical oncologist in Murcia, Spain, has spent months assembling what little evidence exists on one of oncology's most neglected diseases. Bellini's collecting duct carcinoma accounts for less than one percent of kidney tumors — a statistic that, in the world of cancer research, has long translated into abandonment. No dedicated clinical trials. No standard treatment protocol. When the disease spread, patients rarely survived a year.
Determined to find signal in the noise, Lázaro Sánchez and his colleagues reviewed 24 studies, analyzed data from more than 300 patients, and examined 16 individual case reports. What emerged was cautiously remarkable. Some patients treated with immunotherapy combinations achieved complete remission lasting three, five, even six years. One prospective trial showed a 40 percent response rate with ipilimumab and nivolumab, double that of standard treatment. Other immunotherapy-targeted drug combinations produced disease control rates exceeding 80 percent in recent series.
The systematic review does not claim a cure. It claims attention is warranted — and that the disease has been denied it for too long. But Lázaro Sánchez's argument reaches further than one rare tumor. He is describing a structural failure in how oncology distributes its resources, where funding and research follow the most common cancers and rare disease patients are left making life-or-death decisions on borrowed evidence from unrelated conditions.
His prescription is concrete: international registries with centralized pathological review, adaptive trial designs capable of generating insight from small populations, and biomarker-enriched studies to match patients to treatments more precisely. Above all, he calls for a collective commitment from researchers, institutions, and the funding bodies that shape what science gets done.
The review is a beginning. Whether oncology treats it as one depends on whether the field is willing to extend its sense of obligation to the patients it has, until now, largely left behind.
Antonio Lázaro Sánchez, a medical oncologist at Hospital Clínico Universitario Virgen de la Arrixaca, has spent months combing through the scattered evidence on a disease so rare that most oncologists will never see a case. Bellini's collecting duct carcinoma represents less than one percent of all kidney tumors. In the language of cancer research, this statistic carries a weight beyond its numbers: it means neglect.
For years, patients with this disease faced a grim arithmetic. No dedicated clinical trials existed to test new approaches. No standard treatment protocol guided doctors' hands. When the cancer spread beyond the kidney, the median survival stretched barely past twelve months. Patients and their physicians were left to make treatment decisions in near-total darkness, extrapolating from studies of completely different cancers, hoping something might work.
Then Lázaro Sánchez and his colleagues decided to look at what little evidence did exist. They gathered data from twenty-four studies, identified over three hundred patients across observational cohorts, and reviewed sixteen individual case reports. What they found warranted attention. Some patients treated with immunotherapy combinations experienced complete remission that held for three, five, even six years. A prospective trial called SUNNIFORECAST showed that the combination of ipilimumab and nivolumab produced a forty percent response rate in this patient population, compared to twenty percent with standard treatment. Other combinations pairing immunotherapy with targeted drugs showed disease control rates exceeding eighty percent in recent series.
The findings, published as a systematic review, do not claim to have solved the problem. Rather, they signal that a solution may exist—and that this disease deserves serious attention. But the real argument Lázaro Sánchez is making extends far beyond one rare cancer. He is describing a structural problem in how oncology allocates its resources and attention.
Cancer research, he observes, tends to flow toward prevalence like water downhill. More common cancers attract more patients, more funding, more visibility. The logic is sound. But it leaves thousands of patients with rare tumors behind, their treatment decisions made on low-quality evidence, small patient groups, and guesses borrowed from unrelated diseases. These patients become second-class citizens in a field devoted to saving lives.
Fixing this requires more than good intentions. Lázaro Sánchez calls for coordinated international registries with centralized pathological review, so that cases scattered across continents can be studied together. He advocates for adaptive trial designs and basket studies that squeeze maximum information from small sample sizes. He emphasizes the need for prospective research enriched by biomarkers—PD-L1, MET/AXL, HER2—that allow clinicians to select the right patients for the right treatments. Most fundamentally, he demands a collective commitment from researchers, clinicians, institutions, and the funding bodies that decide what gets supported and what does not.
The systematic review on Bellini's collecting duct carcinoma is a beginning. But Lázaro Sánchez is clear that the next steps must be taken together, by everyone with power in the system. The question now is whether oncology will answer the call.
Notable Quotes
Cancer research tends, almost by gravity, towards what is prevalent: more patients, more funding, more visibility. But that logic leaves behind thousands of patients with rare tumors.— Antonio Lázaro Sánchez
The signal exists—and this disease deserves to be heard.— Antonio Lázaro Sánchez
The Hearth Conversation Another angle on the story
Why does a disease affecting less than one percent of kidney cancer patients warrant this much attention?
Because those patients still exist, and they still die. One percent of kidney cancers is still hundreds of people every year. But more than that—the problem Bellini's carcinoma represents is systemic. It shows us how research funding follows prevalence, not need.
The immunotherapy combinations showed real responses. Why hasn't this been pursued more aggressively?
Because there's no economic incentive and no critical mass of patients to justify a large trial. Pharmaceutical companies need volume. Researchers need funding. When you have three hundred patients worldwide, you don't get either. So the evidence stays scattered, anecdotal, unpublished.
You mentioned some patients had remissions lasting six years. That's extraordinary.
It is. And it's almost accidental—we only know about it because someone documented it. Imagine how many other signals we're missing in diseases where cases are even rarer, where doctors don't publish, where patients never connect with each other.
What would actually change if the system listened to this call?
International registries would mean every case gets recorded, reviewed by experts, added to a growing knowledge base. Adaptive trials would let us test combinations faster with fewer patients. Biomarker studies would help us predict who responds. Right now we're flying blind. That could change.
Is this just about Bellini's carcinoma, or is it a template for something larger?
It's a template. There are thousands of rare cancers. Each one has patients who deserve better than guesswork. This is about whether oncology will commit to equity—whether research serves everyone or just the statistically convenient.